Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Cancer Research

• Publication date

  1988-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 3390813
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The chemotherapy of posterior Fossa tumors in childhood

  2004cited by this paper
• Phenotypic Analysis of Four Human Medulloblastoma Cell Lines and Transplantable Xenografts

  1989cited by this paper
• Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc.

  1988cited by this paper
• Structural chromosomal abnormalities in human medulloblastoma.

  1988cited by this paper
• Differentiation in the medulloblastoma. A histological and immunohistochemical study.

  1987cited by this paper
• The use of experimental models of human medulloblastoma in the design of rational therapy

  1986cited by this paper
• Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.

  1986cited by this paper
• Experimental chemotherapy of human medulloblastoma with classical alkylators.

  1986cited by this paper
• Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.

  1986cited by this paper
• Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease.

  1986cited by this paper
• Neuronal and glial proteins in medulloblastomas. II. Heterotransplantation of human medulloblastoma.

  1986cited by this paper
• Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.

  1986cited by this paper
• Synthesis and Antitumor Activity of Cyclophosphamide Analogues.

  1986cited by this paper
• Establishment of a Human Medulloblastoma Cell Line and Its Heterotransplantation into Nude Mice

  1985cited by this paper
• Neuron-specific enolase and neurofilament protein as markers of differentiation in medulloblastoma.

  1985cited by this paper
• Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med

  1985cited by this paper
• A Model for Human Medulloblastoma Growth, Morphology, and Chromosomal Analysis in Vitro and in Athymic Mice

  1983cited by this paper
• Primitive neuroectodermal tumors of the central nervous system.

  1983cited by this paper
• Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

  1983cited by this paper
• Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.

  1983cited by this paper
• The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors.

  1983cited by this paper
• Medulloblastoma in children: increasing survival rates and further prospects.

  1982cited by this paper
• Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma.

  1981cited by this paper
• Growth and Chemotherapeutic Response in Athymic Mice of Tumors Arising from Human Glioma‐derived Cell Lines

  1981cited by this paper
• High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children.

  1981influential reference
• Astrocytic differentiation in medulloblastoma.

  1980cited by this paper
• Establishment of a human medulloblastoma cell line

  1977cited by this paper
• Intrathecal n, n′, n′‐triethylenethiophosphoramide [thio‐tepa (NSC 6396)] in the treatment of malignant meningeal disease. Phase I‐II study

  1976cited by this paper
• A manual on quantitative drug evaluation in experimental tumor systems.

  1962cited by this paper
• Brain tumors in children.

  1958cited by this paper

• Opportunities in the translational pipeline for pediatric brain cancer therapies

  2025cites this paper
• Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma

  2024cites this paper
• Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma

  2021cites this paper
• A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

  2021cites this paper
• Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

  2018cites this paper
• Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status

  2018cites this paper
• The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival

  2017cites this paper
• Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

  2016cites this paper
• Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

  2015cites this paper
• Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development

  2015cites this paper
• Treatment for Glioblastoma Reversing the Warburg Effect as a Metabolism

  2014cites this paper
• Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

  2014cites this paper
• Reversing the Warburg Effect as a Treatment for Glioblastoma*

  2013cites this paper
• -deoxyguanosine and Bcnu ′ -benzyl-2 6 O Treatment of Human Brain Tumor Xenografts with Updated Version Citing Articles E-mail Alerts Treatment of Human Brain Tumor Xenografts with 06-benzyl-2'-deoxyguanosine and Bcnu1

  2013cites this paper
• Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors

  2013cites this paper
• The integrated landscape of driver genomic alterations in glioblastoma

  2013cites this paper
• Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

  2013cites this paper
• Induction of the Unfolded Protein Response Drives Enhanced Metabolism and Chemoresistance in Glioma Cells

  2013cites this paper
• Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

  2013cites this paper
• Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

  2013cites this paper
• Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program

  2012cites this paper
• Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program

  2012cites this paper
• Genomic Analysis of Pathway Signaling in Glioblastoma and Other Cancers

  2012cites this paper
• Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233

  2012cites this paper
• Testing of the Akt/PKB inhibitor MK‐2206 by the pediatric preclinical testing program

  2012cites this paper
• Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

  2012cites this paper
• Pediatric Preclinical Testing Program (PPTP) – May 2012

  2012cites this paper
• Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program

  2012cites this paper
• Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

  2012cites this paper
• Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program

  2012cites this paper
• Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model

  2012cites this paper
• Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling

  2012cites this paper
• Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program

  2012cites this paper
• Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

  2012cites this paper
• Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

  2011cites this paper
• Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program

  2011cites this paper
• Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors.

  2011cites this paper
• Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

  2011cites this paper
• Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program

  2011cites this paper
• Initial testing of lenalidomide by the pediatric preclinical testing program

  2011cites this paper
• Radioiodinated O(6)-Benzylguanine derivatives containing an azido function.

  2011cites this paper
• Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models

  2011cites this paper
• Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program

  2010cites this paper
• On the biological activity of drug molecules: Busulfan and nabumetone

  2010cites this paper
• Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program

  2010cites this paper
• Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

  2010cites this paper
• Initial testing of topotecan by the pediatric preclinical testing program

  2010cites this paper
• Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models.

  2010cites this paper
• Initial testing (stage 1) of the multi‐targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

  2010cites this paper
• Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

  2010cites this paper
• Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing program

  2010cites this paper
• Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program

  2010cites this paper
• Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

  2010cites this paper
• Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing program

  2009cites this paper
• Initial testing of aplidin by the pediatric pre‐clinical testing program

  2009cites this paper
• Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program

  2009cites this paper
• Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

  2009cites this paper
• Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17‐DMAG, KOS‐1022) by the pediatric preclinical testing program

  2008cites this paper
• Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

  2008cites this paper
• Initial testing of cisplatin by the pediatric preclinical testing program

  2008cites this paper
• Initial testing of dasatinib by the pediatric preclinical testing program

  2008cites this paper
• Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program

  2008cites this paper
• Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

  2008cites this paper
• Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

  2008cites this paper
• Multiagent chemotherapy studied in a xenograft model of medulloblastoma/primitive neuroectodermal tumour: analysis of the VETOPEC regimen.

  2008cites this paper
• Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program

  2008cites this paper
• Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program

  2008cites this paper
• Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children

  2007cites this paper
• The pediatric preclinical testing program: Description of models and early testing results

  2007cites this paper
• Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.

  2007cites this paper
• Overexpressed WAFl / Cipl Renders Glioblastoma Cells Resistant to Chemotherapy Agents l , 3-Bis ( 2-chloroethyl )-l-nitrosourea and Cisplatin 1

  2006cites this paper
• Synergistic Interactions between Cyclophosphamide or Melphalan and VP-16 in a Human Rhabdomyosarcoma Xenograft 1

  2006cites this paper
• Cyclophosphamide Resistance in Medulloblastoma1

  2006cites this paper
• Chemotherapy in neoplastic meningitis.

  2006cites this paper
• Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine.

  2006cites this paper
• Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model

  2005cites this paper
• O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT).

  2005cites this paper
• A long surviving case of recurrent medulloblastoma displaying effectiveness of ACNU/vincristine chemotherapy

  2005cites this paper
• Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

  2005cites this paper
• Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models

  2005cites this paper
• Pharmacokinetics Following Intraventricular Administration of Chemotherapy in Patients with Neoplastic Meningitis

  2005cites this paper
• ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

  2005cites this paper
• Cyclosphosphamide therapy of medulloblastoma: From the laboratory to the clinic and back again (and again and again)

  2005cites this paper
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cites this paper
• Busulfan therapy of central nervous system xenografts in athymic mice

  2004cites this paper
• O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase.

  2004cites this paper
• Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI)

  2004cites this paper
• The role of xenografting in pediatric brain tumor research with specific emphasis on medulloblastoma/primitive neuroectodermal tumors of childhood.

  2003cites this paper
• High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.

  2003cites this paper
• Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?

  2002cites this paper
• Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma

  2002cites this paper
• O6-benzylguanine-mediated enhancement of chemotherapy.

  2002cites this paper
• Tumors Of The Brain Stem, Cerebellum, and Fourth Ventricle

  2002cites this paper
• O 6-Benzylguanine-mediated Enhancement of Chemotherapy 1

  2002cites this paper
• Current Options for the Treatment of Neoplastic Meningitis

  2002cites this paper
• Features of proliferation and in vitro drug resistance in central primitive neuro‐ectodermal tumours

  2002cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• Single Agent and in Combination Chemotherapy asPrimitive Neuroectodermal Tumor / Medulloblastoma Models Antitumor Activity of the Rapamycin Analog CCI-779 in Human Updated

  2001cites this paper
• Medulloblastoma/primitive neuroectodermal tumour studied as a Matrigel enhanced subcutaneous xenograft model.

  2001cites this paper
• Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts

  2001cites this paper